and
Empire Genomics
announced the formation of a strategic alliance.
ICON and Empire Genomics will partner to develop a service portfolio tailored to the development of personalized medicines. The partnership combines Empire Genomics’ expertise in pharmacogenomics, computational modeling of disease state, drug disposition and drug targets with ICON’s expertise in translational medicine, clinical trial design, and biomarkers. The combined service offering will enable the identification of responder target populations, permit the stratification of patients through the development and use of companion diagnostics and will streamline drug development programs through the generation and analysis of relevant data obtained in the pre-clinical and early stage clinical setting.
“We look to partner with companies, scientists, and research institutions that complement our corporate strategies and experience, and this collaboration gives us the opportunity to work with industry leading clinical units, translational medicine expertise, and the broader ICON full-service offering,” commented Anthony Johnson, Chief Executive Officer, Empire Genomics.
“Genomics plays an integral role in personalized medicine, and through our collaboration with Empire Genomics, we can now offer sponsors integrated personalized medicine services,” commented Dr. Cyril Clarke, Vice President Translational Medicine, ICON Development Solutions. “We believe that this partnership will help sponsors to speed development by enhancing target population identification to ultimately produce safer, more effective medicines.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.